Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally
Loading...